The University of Chicago Header Logo

Connection

Nitasha Sarswat to Aged

Back to Details
This is a "connection" page, showing publications Nitasha Sarswat has written about Aged.
Nitasha Sarswat
Connection Strength
0.616
Aged
  1. Continuous Remote Patient Monitoring in Heart Failure Patients: The Heart Failure Cascade Study: Phase II and III Outcomes. Appl Clin Inform. 2026 Aug; 17(4):789-801.
    View in: PubMed
    Score: 0.017
  2. Incremental prognostic value of cardiac magnetic resonance beyond biomarker staging in transthyretin cardiac amyloidosis. Eur Heart J Cardiovasc Imaging. 2026 Sep 01; 27(9):1603-1612.
    View in: PubMed
    Score: 0.017
  3. Effect of Vutrisiran According to Baseline Tafamidis Use in Transthyretin Amyloidosis With Cardiomyopathy: Insights From HELIOS-B. J Am Coll Cardiol. 2026 Sep 22; 88(12):1402-1412.
    View in: PubMed
    Score: 0.017
  4. Natriuretic Peptide and Transthyretin and Their Relationship With Clinical Outcomes: Results From ATTRIBUTE-CM, a Randomized Controlled Trial. J Am Heart Assoc. 2026 Oct 06; 15(19):e050566.
    View in: PubMed
    Score: 0.017
  5. Multimodal Artificial Intelligence for Cardiac Amyloidosis Diagnosis: Integrating Echocardiography With Clinical and Laboratory Data for Improved Detection. Circ Cardiovasc Imaging. 2026 Jun; 19(6):e019610.
    View in: PubMed
    Score: 0.017
  6. Long-Term Durability of Acoramidis Efficacy in Transthyretin Amyloid Cardiomyopathy: Open-Label Extension of the ATTRibute-CM Randomized Clinical Trial. JAMA Cardiol. 2026 05 01; 11(5):446-454.
    View in: PubMed
    Score: 0.017
  7. Acoramidis, Serum Transthyretin, and Cardiovascular Outcomes in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM Trial. J Card Fail. 2026 May; 32(5):864-876.
    View in: PubMed
    Score: 0.017
  8. Efficacy of Acoramidis in Wild-Type and Variant Transthyretin Amyloid Cardiomyopathy: Results From ATTRibute-CM and Its Open-Label Extension. JAMA Cardiol. 2026 01 01; 11(1):57-67.
    View in: PubMed
    Score: 0.016
  9. Coramitug, a Humanized Monoclonal Antibody for the Treatment of Transthyretin Amyloid Cardiomyopathy: A Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial. Circulation. 2026 Jan 27; 153(4):214-225.
    View in: PubMed
    Score: 0.016
  10. Cardiac amyloidosis detection from a single echocardiographic video clip: a novel artificial intelligence-based screening tool. Eur Heart J. 2025 10 22; 46(40):4090-4101.
    View in: PubMed
    Score: 0.016
  11. Disparities in diagnosis and outcomes in American patients with transthyretin cardiac amyloidosis. Int J Cardiovasc Imaging. 2025 Aug; 41(8):1487-1496.
    View in: PubMed
    Score: 0.016
  12. Early Increase in Serum Transthyretin by Acoramidis Independently Predicts Improved Survival in TTR Amyloid Cardiomyopathy. J Am Coll Cardiol. 2025 May 27; 85(20):1911-1923.
    View in: PubMed
    Score: 0.015
  13. Mitigating Post-operative Right Ventricular Dysfunction After Left Ventricular Assist Device: The RV Protection Study. J Card Fail. 2026 Jan; 32(1):46-57.
    View in: PubMed
    Score: 0.015
  14. Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM Trial. Circulation. 2025 Mar 04; 151(9):601-611.
    View in: PubMed
    Score: 0.015
  15. Perivascular Amyloid Deposition in Immunoglobulin Light Chain Cardiac Amyloidosis and Its Implications on Echocardiographic Cardiac Remodeling. J Am Soc Echocardiogr. 2024 10; 37(10):1010-1012.
    View in: PubMed
    Score: 0.015
  16. Defining echocardiographic predictors of outcome in cardiac amyloidosis by subtype. Curr Probl Cardiol. 2024 Sep; 49(9):102729.
    View in: PubMed
    Score: 0.015
  17. Limitations of apical sparing pattern in cardiac amyloidosis: a multicentre echocardiographic study. Eur Heart J Cardiovasc Imaging. 2024 05 31; 25(6):754-761.
    View in: PubMed
    Score: 0.014
  18. Prevalence of valvular heart disease in cardiac amyloidosis and impact on survival. Curr Probl Cardiol. 2024 Apr; 49(4):102417.
    View in: PubMed
    Score: 0.014
  19. Non-invasive diagnosis of transthyretin cardiac amyloidosis utilizing typical late gadolinium enhancement pattern on cardiac magnetic resonance and light chains. Eur Heart J Cardiovasc Imaging. 2023 05 31; 24(6):829-837.
    View in: PubMed
    Score: 0.013
  20. The prognostic role of advanced hemodynamic variables in patients with left ventricular assist devices. Artif Organs. 2023 Mar; 47(3):574-581.
    View in: PubMed
    Score: 0.013
  21. Prevalence of Right Atrial Impairment and Association with Outcomes in Cardiac Amyloidosis. J Am Soc Echocardiogr. 2022 08; 35(8):829-835.e1.
    View in: PubMed
    Score: 0.012
  22. Increased Rate of Pump Thrombosis and Cardioembolic Events Following Ventricular Tachycardia Ablation in Patients Supported With Left Ventricular Assist Devices. ASAIO J. 2020 Nov/Dec; 66(10):1127-1136.
    View in: PubMed
    Score: 0.011
  23. Early experience of COVID-19 in 2 heart transplant recipients: Case reports and review of treatment options. Am J Transplant. 2020 10; 20(10):2916-2922.
    View in: PubMed
    Score: 0.011
  24. Estimation of Central Venous Pressure by Pacemaker Lead Impedances in Left Ventricular Assist Device Patients. ASAIO J. 2020 01; 66(1):49-54.
    View in: PubMed
    Score: 0.011
  25. Combined Left Ventricular Assist Device and Coronary Artery Bypass Grafting Surgery: Should We Bypass the Bypass? ASAIO J. 2020 01; 66(1):32-37.
    View in: PubMed
    Score: 0.011
  26. Surgical device exchange provides improved clinical outcomes compared to medical therapy in treating continuous-flow left ventricular assist device thrombosis. Artif Organs. 2020 Apr; 44(4):367-374.
    View in: PubMed
    Score: 0.011
  27. Metabolic Dysfunction in Continuous-Flow Left Ventricular Assist Devices Patients and Outcomes. J Am Heart Assoc. 2019 11 19; 8(22):e013278.
    View in: PubMed
    Score: 0.011
  28. Discordance Between Clinical Assessment and Invasive Hemodynamics in Patients With Advanced Heart Failure. J Card Fail. 2020 Feb; 26(2):128-135.
    View in: PubMed
    Score: 0.010
  29. A subcostal approach is favorable compared to sternotomy for left ventricular assist device exchange field of research: artificial heart (clinical). J Artif Organs. 2019 Sep; 22(3):181-187.
    View in: PubMed
    Score: 0.010
  30. The Effects of Hemodynamic Unloading in African Americans Implanted with Left Ventricular Assist Devices. ASAIO J. 2019 02; 65(2):e15-e17.
    View in: PubMed
    Score: 0.010
  31. Impact of Cardiac Resynchronization Therapy on Left Ventricular Unloading in Patients with Implanted Left Ventricular Assist Devices. ASAIO J. 2019 02; 65(2):117-122.
    View in: PubMed
    Score: 0.010
  32. Optimal Hemodynamics During Left Ventricular Assist Device Support Are Associated With Reduced Readmission Rates. Circ Heart Fail. 2019 02; 12(2):e005094.
    View in: PubMed
    Score: 0.010
  33. Optimal haemodynamics during left ventricular assist device support are associated with reduced haemocompatibility-related adverse events. Eur J Heart Fail. 2019 05; 21(5):655-662.
    View in: PubMed
    Score: 0.010
  34. A histopathologic schema to quantify the burden of cardiac amyloidosis: Relationship with survival and echocardiographic parameters. Echocardiography. 2019 02; 36(2):285-291.
    View in: PubMed
    Score: 0.010
  35. Improvement in Biventricular Cardiac Function After Ambulatory Counterpulsation. J Card Fail. 2019 Jan; 25(1):20-26.
    View in: PubMed
    Score: 0.010
  36. Repeated Ramp Tests on Stable LVAD Patients Reveal Patient-Specific Hemodynamic Fingerprint. ASAIO J. 2018 Nov/Dec; 64(6):701-707.
    View in: PubMed
    Score: 0.010
  37. Omega-3 Therapy Is Associated With Reduced Gastrointestinal Bleeding in Patients With Continuous-Flow Left Ventricular Assist Device. Circ Heart Fail. 2018 10; 11(10):e005082.
    View in: PubMed
    Score: 0.010
  38. Impact of Residual Valve Disease on Survival After Implantation of Left Ventricular Assist Devices. Ann Thorac Surg. 2018 12; 106(6):1789-1796.
    View in: PubMed
    Score: 0.010
  39. Echocardiographic Predictors of Hemodynamics in Patients Supported With Left Ventricular Assist Devices. J Card Fail. 2018 Sep; 24(9):561-567.
    View in: PubMed
    Score: 0.010
  40. Increased Risk of Bleeding in Left Ventricular Assist Device Patients Treated with Enoxaparin as Bridge to Therapeutic International Normalized Ratio. ASAIO J. 2018 Mar/Apr; 64(2):140-146.
    View in: PubMed
    Score: 0.009
  41. Long-Acting Octreotide Reduces the Recurrence of Gastrointestinal Bleeding in Patients With a Continuous-Flow Left Ventricular Assist Device. J Card Fail. 2018 Apr; 24(4):249-254.
    View in: PubMed
    Score: 0.009
  42. Predictors of Hemodynamic Improvement and Stabilization Following Intraaortic Balloon Pump Implantation in Patients With Advanced Heart Failure. J Invasive Cardiol. 2018 02; 30(2):56-61.
    View in: PubMed
    Score: 0.009
  43. HVAD Waveform Analysis as a Noninvasive Marker of Pulmonary Capillary Wedge Pressure: A First Step Toward the Development of a Smart Left Ventricular Assist Device Pump. ASAIO J. 2018 Jan/Feb; 64(1):10-15.
    View in: PubMed
    Score: 0.009
  44. Decoupling Between Diastolic Pulmonary Artery Pressure and Pulmonary Capillary Wedge Pressure as a Prognostic Factor After Continuous Flow Ventricular Assist Device Implantation. Circ Heart Fail. 2017 Sep; 10(9).
    View in: PubMed
    Score: 0.009
  45. Cardiac Output Assessment in Patients Supported with Left Ventricular Assist Device: Discordance Between Thermodilution and Indirect Fick Cardiac Output Measurements. ASAIO J. 2017 Jul/Aug; 63(4):433-437.
    View in: PubMed
    Score: 0.009
  46. The Hemodynamic Effects of Aortic Insufficiency in Patients Supported With Continuous-Flow Left Ventricular Assist Devices. J Card Fail. 2017 Jul; 23(7):545-551.
    View in: PubMed
    Score: 0.009
  47. 3D Morphological Changes in LV and RV During LVAD Ramp Studies. JACC Cardiovasc Imaging. 2018 02; 11(2 Pt 1):159-169.
    View in: PubMed
    Score: 0.009
  48. Surgically Corrected Mitral Regurgitation During Left Ventricular Assist Device Implantation Is Associated With Low Recurrence Rate and Improved Midterm Survival. Ann Thorac Surg. 2017 Mar; 103(3):725-733.
    View in: PubMed
    Score: 0.008
  49. Plasma Serotonin in Heart Failure: Possible Marker and Potential Treatment Target. Heart Lung Circ. 2017 May; 26(5):442-449.
    View in: PubMed
    Score: 0.008
  50. Screening for Outflow Cannula Malfunction of Left Ventricular Assist Devices (LVADs) With the Use of Doppler Echocardiography: New LVAD-Specific Reference Values for Contemporary Devices. J Card Fail. 2016 Oct; 22(10):808-14.
    View in: PubMed
    Score: 0.008
  51. Association between endothelial function and chronotropic incompetence in subjects with chronic heart failure receiving optimal medical therapy. Echocardiography. 2010 Mar; 27(3):294-9.
    View in: PubMed
    Score: 0.005
  52. Interdependence of cardiac and endothelial function in patients with symptomatic chronic heart failure of nonischemic etiology. Echocardiography. 2009 Sep; 26(8):916-21.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.